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 Introduction 
 Pathological myopia is a major cause of irreversible vi-
sion loss, and is the fourth to ninth most frequent cause 
of blindness in the world  [1–6] . Importantly, pathological 
myopia is the primary cause of choroidal neovasculariza-
tion (CNV) in individuals younger than 50 years  [7, 8] . 
Myopic maculopathy is the primary cause of vision loss 
associated with high myopia  [9–11] , and the classification 
made by Avila et al.  [12]  has been the most widely used 
until recently. However, it is not consensual, as stated by 
Hayashi et al.  [10] , because it is not based on the actual 
progression pattern and includes posterior staphyloma in 
the classification. Hayashi et al.  [10]  recently suggested a 
new classification system based on the progression pat-
tern of myopic maculopathy: tessellated fundus, diffuse 
chorioretinal atrophy, patchy chorioretinal atrophy, lac-
quer cracks, active CNV and macular atrophy.
 Few studies have been made in order to analyze the 
progression pattern of myopic maculopathy and long-
term visual prognosis  [4, 9, 10] . Besides, the impact of dif-
ferent treatments for myopic CNV on them has not been 
addressed so far. Until recently, photodynamic therapy 
(PDT) with verteporfin (Visudyne ® ) was the only ap-
proved treatment for myopic CNV  [7, 13, 14] ; however, in 
the last few years several studies also reported good results 
with anti-vascular endothelial growth factor (VEGF) 
drugs, without significant complications  [15–20] , and the 
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 Abstract 
 Purpose: To evaluate the long-term progression of myopic 
maculopathy and functional outcome after treatment of my-
opic choroidal neovascularization (CNV) with photodynamic 
therapy (PDT) and/or intravitreal ranibizumab (IVR).  Meth-
ods: Retrospective study with a cross-sectional evaluation. 
Eyes were assigned to 4 groups (PDT, IVR, PDT + IVR, dry my-
opic maculopathy) and evaluated with best-corrected visual 
acuity, color fundus photography and spectral-domain opti-
cal coherence tomography. Chorioretinal atrophy progres-
sion was quantified.  Results: Fifty-four eyes were included 
with a mean follow-up of 80.6 ± 28.0 months. The prevalence 
of diffuse, patchy and macular atrophy increased during the 
follow-up, in contrast with tessellated fundus, lacquer cracks 
and active CNV. Progression of macular atrophy was signifi-
cant in the 3 treatment groups (p < 0.05) and predictive of 
visual acuity. It depended on age, degree of myopia and 
presence of staphyloma, but not on the type of treatment. 
 Conclusions: The long-term functional outcome of eyes 
with myopic CNV is more dependent on the progression of 
macular atrophy, and not on the type of treatment. 
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European Medicines Agency recently approved ranibi-
zumab for the treatment of myopic CNV in Europe.
 The purpose of this study is to evaluate the functional 
and morphological progression of myopic maculopathy 
on a long-term basis in eyes with myopic CNV treated 
with PDT, intravitreal ranibizumab (IVR), or IVR after 
PDT failure.
 Material and Methods 
 A retrospective study was conducted at the Ophthalmology 
Department of the Centro Hospitalar e Universitário de Coimbra 
and at the Association for Innovation and Biomedical Research on 
Light and Image. Written informed consent was obtained from all 
subjects, and the study was conducted in accordance with the te-
nets of the Declaration of Helsinki and after institutional review 
board approval.
 The medical records of consecutive patients with pathological 
myopia followed in our Department were examined. The inclusion 
criteria were: (1) highly myopic eyes, defined as having a spherical 
equivalent (SE) refractive error equal or more negative than 
–6.00 dpt and/or axial length (AL) equal or superior to 26.0 mm; (2) 
CNV treated with PDT and/or IVR, without other previous treat-
ments; (3) a minimum follow-up of 3 years if treated with IVR alone, 
or 5 years if treated with PDT alone or PDT and IVR; (4) contralat-
eral highly myopic eyes that never developed CNV with a minimum 
follow-up of 3 years. The exclusion criteria were: history of amblyo-
pia, glaucoma, uveitis, dense cataract, diabetic retinopathy, retinal 
vascular abnormalities, laser treatment, intravitreous injection of 
triamcinolone, previous vitrectomy and scleral buckling procedure.
 Eyes with a history of myopic CNV meeting the inclusion cri-
teria were assigned to 3 groups according to treatment received 
during the follow-up: PDT only, IVR only and PDT + IVR. The 
kind of treatment used for myopic CNV in the included eyes was 
determined as follows: after PDT approval for the treatment of 
myopic CNV, this was the standard treatment used in our Depart-
ment, and eyes treated with PDT only were included in the PDT 
group; however, after IVR approval for the treatment of CNV sec-
ondary to age-related macular degeneration, new cases of myopic 
CNV were treated with IVR after an informed consent – this be-
came the IVR group. Eyes with myopic CNV first treated with PDT 
but with poor response or relapsing CNV were switched to IVR 
during the follow-up, after informed consent, and included in the 
PDT + IVR group. Both treatments were never performed simul-
taneously during the follow-up. Fluorescein angiography and opti-
cal coherence tomography (OCT) were always performed before 
starting treatment for myopic CNV in all treated eyes (PDT, IVR 
and PDT + IVR). During the follow-up, retreatment with PDT was 
performed if leakage was present in fluorescein angiography. Re-
treatment with IVR was performed when active myopic CNV was 
clinically suspected and based on the presence of fluid in the OCT, 
best-corrected visual acuity (BCVA) loss associated with meta-
morphopsia and/or macular hemorrhage. Fluorescein angiogra-
phy was also performed before retreatment with IVR if considered 
necessary. A fourth group – ‘dry myopic maculopathy’ – included 
the contralateral highly myopic eyes without history of CNV, 
which never required any treatment.
 The patients’ medical records were reviewed for data, including 
demographic characteristics, initial refraction, BCVA with Early 
Treatment of Diabetic Retinopathy Study (ETDRS) charts during 
follow-up, number and kind of treatments performed for myopic 
CNV and surgical treatments. Color fundus photographs were also 
selected for the longitudinal analysis of myopic maculopathy pro-
gression.
 A cross-sectional evaluation was performed in all patients in-
cluding BCVA using ETDRS charts, slitlamp examination and di-
lated fundus stereoscopic examination with +90- and +60-dpt 
lenses. Presence of posterior staphyloma was recorded and classi-
fication performed according to Curtin  [21] . In phakic patients the 
manifest refraction was recorded, but it was excluded in patients 
who had cataract or refractive surgery during the follow-up. Mea-
surement of axial length was performed with Biograph Allegro ® 
(WaveLight AG, Erlangen, Germany) or by A-scan ultrasonogra-
phy (OcuScan ® RxP, Alcon, Calif., USA) if the previous failed. 
Color fundus photography and fundus autofluorescence (FAF; 
Heidelberg Engineering, Heidelberg, Germany) were performed 
for classification of myopic maculopathy. Spectral- domain OCT 
was performed with Spectralis OCT (Heidelberg Engineering).
 The areas of macular, patchy and peripapillary atrophy were 
measured manually by a certified grader in all color fundus pho-
tographs and also in the FAFs performed during the last visit, using 
RetmarkerAMD ® software (Critical Health SA, Portugal), a semi-
automated system. This software divides the posterior pole into 10 
subfields with a circular grid centered in the macula and calibrated 
through the edges of the papilla, identical to the ETDRS-style mac-
ular grid (which comprises 1-, 3- and 6-mm concentric circles) 
 [22] . The central subfield 1 overlaps the central macula. Total and 
central subfield 1 areas were calculated for each type of atrophy in 
the selected examinations, so it was possible to precisely locate and 
measure their progression over time ( fig. 1 ).
 Classification of myopic maculopathy in the selected color fun-
dus photographs was made by 2 of the authors (C.L.F., R.M.S.) 
independently, and in accordance with the progression pattern 
proposed by Hayashi et al.  [10] . In cases of disagreement, the color 
fundus photographs were assessed jointly until a consensus was 
reached.
 Statistical analyses were performed using the STATA software 
version 12.0 (StataCorp LP). Data was presented descriptively and 
analyzed statistically. First univariate analyses were performed to 
identify statistically significant results. To test for statistically signifi-
cant differences between independent groups, the Mann-Whitney 
test was used, while for paired groups the Wilcoxon test was used. 
Correlations between parameters were tested using the Spearman 
correlation coefficient. A multivariate analysis was performed there-
after using regression models to identify risk factors for BCVA and 
macular atrophy. Quantile regression models were performed con-
sidering treatment, demographic and ophthalmological variables 
(first model) and considering the retinal lesions (second model).
 Results 
 Patient Demographic Data 
 Fifty-four eyes of 30 patients (20 females and 10 males) 













   
   
   
   
   
   
   
   
   
   
   
   
   
   

























sion criteria. Fifteen eyes (27.8%) were included in the 
PDT group, 10 eyes (18.5%) in the IVR group, 13 eyes 
(24.1%) in the PDT + IVR group and 16 eyes (29.6%) in 
the dry maculopathy group. Initial and final mean age, 
refractive error, axial length at the last visit, BCVA evolu-
tion and follow-up of all eyes and by group are presented 
in  table 1 . No statistically significant differences between 
the 4 groups were found with respect to the initial and 
final age, refractive error or axial length (p > 0.05).
 The mean number of PDT and IVR treatments per-
formed in each group and the largest mean spot used in 
PDT are presented in  table 2 . Ten eyes (19%) were pseu-
dophakic (2 in the PDT group, 3 in the IVR group, 2 in 
the PDT + IVR group and 3 in the dry maculopathy 
group), and 2 eyes (4%) were aphakic (1 eye both in the 
PDT and dry maculopathy groups). Four eyes (7%) of 2 
patients were submitted previously to refractive surgery 
(2 in the PDT + IVR group, 1 in the IVR group and 1 in 
the dry maculopathy group). 
 Characterization and Progression of Myopic 
Maculopathy 
 The progression patterns found in the 4 groups during 
follow-up are presented in  figure 2 . The prevalence of dif-
fuse and patchy atrophy increased during the follow-up, 
but the rates of tessellated fundus and lacquer cracks were 
lower and tended to decrease or remain constant. The ex-
ception to this pattern was the IVR group. The presence 
of active CNV decreased in all treatment groups with a 
reciprocal increase in macular atrophy throughout the 
follow-up. The majority of treated eyes (89%) presented 
with subfoveal CNV at the beginning of the follow-up, 5 
Table 1.  Summary of clinical data of all eyes and by group
All eyes PDT IVR PDT + IVR Dry maculopathy
Age, years
Initial 49.1±14.9 50.3±12.1 53.8±9.8 45.5±19.9 47.8±15.6
Final 55.4±15.2 58.5±12.2 57.4±9.4 52.1±20.3 54.0±16.3




Initial 55.0±21.9 43.7±22.9 60.1±6.3 59.7±15.2 58.5±28.7
36-month follow-up/before IVR – 51.5±24.3 – 50.8±14.4 61.1±28.5
Final 56.4±24.1 45.5±25.7 60.5±20.1 58.8±18.6 62.3±27.3
SE, dpt
Initial –14.3±5.0 –16.3±6.6 –16.4±5.3 –13.9±3.7 –11.8±4.0
Final –15.3±5.4 –17.2±6.6 –14.1±5.0 –15.8±4.8 –13.0±4.2
AL at final visit, mm 29.8±2.1 30.7±1.9 29.7±2.3 29.9±2.3 29.3±1.9
 Data are shown as means ± standard deviation.
 Fig. 1. Measurement of the areas of atrophy 
in color fundus photographs ( a ) and FAFs 



























   
   
   
   
   
   
   
   
   
   
   
   
   
   

























eyes (9%) had juxtafoveal CNV, and only 1 eye (2%) had 
extrafoveal CNV. Of the 30 patients included in the study, 
with a mean follow-up of 6.7 years, 10 developed CNV in 
the contralateral eye. This corresponds to a bilaterality 
rate of 33%.
 A posterior staphyloma was identified by binocular 
stereoscopic fundus examination in 29 eyes (54%) in the 
last visit. Staphylomas type I (n = 12; 22%) and type II (n = 
10; 19%) were the most common, followed by type IV 
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 Fig. 2. Progression of myopic maculopathy in the 4 groups.  a PDT.  b IVR.  c PDT + IVR.  d Dry myopic maculopathy. 
Table 2.  Number of treatments performed in each group and largest mean spot used in the groups treated with 
PDT
PDT IVR PDT + IVR
Number of treatments with IVR – 7.7±4.8 5.9±2.6
Number of treatments with PDT 4.1±3.0 – 3.5±2.1
Largest spot used in PDT, μm 2,866.7±1,090.7 – 3,180.8±848.4













   
   
   
   
   
   
   
   
   
   
   
   
   
   

























 The main associated features found on OCT in the last 
visit were: epiretinal membrane in 17% (n = 9) of all eyes, 
vitreomacular traction in 15% (n = 8) and myopic schisis 
in 11% (n  = 6). Myopic schisis affecting the fovea was 
found only in 1 eye (PDT group).
 Progression of Chorioretinal Atrophy 
 The progression of the total and central areas of each 
type of chorioretinal atrophy in the color fundus photo-
graphs is presented in  table 3 and  figure 3 . Progression of 
the total and central areas of macular atrophy was statisti-
 Fig. 3. Progression of the total areas of macular ( a ), patchy ( b ) and peripapillary ( c ) atrophy measured in the selected color fundus pho-
tographs, by group. Note: the areas are presented in square millimeters. 
Table 3.  Progression of the areas of myopic chorioretinal atrophy in the selected color fundus photographs, by group
PDT IVR PDT + IVR Dry maculopathy
Peripapillary atrophy – total area
Initial 6.1±8.8 5.0±2.6 4.0±1.9 3.9±3.7
36-month follow-up/before IVR 8.5±11.3 – 6.0±4.0 5.3±5.2
Final 13.3±13.7 5.5±2.7 8.2±4.4 7.2±9.0
Peripapillary atrophy – central subfield 1 area
Initial 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0
36-month follow-up/before IVR 0.1±0.2 – 0.0±0.0 0.0±0.0
Final 0.2±0.4 0.0±0.0 0.0±0.2 0.1±0.2
Patchy atrophy – total area
Initial 1.5±3.2 0.1±0.2 0.2±0.4 1.8±3.9
36-month follow-up/before IVR 2.3±3.5 – 0.9±1.2 1.4±3.0
Final 3.8±5.5 0.1±0.1 1.8±1.7 1.8±4.0
Patchy atrophy – central subfield 1 area
Initial 0.0±0.1 0.0±0.0 0.0±0.0 0.0±0.0
36-month follow-up/before IVR 0.0±0.0 – 0.0±0.0 0.0±0.0
Final 0.1±0.2 0.0±0.0 0.0±0.0 0.0±0.0
Macular atrophy – total area
Initial 0.6±2.0 0.3±0.9 0.0±0.0 0.7±1.5
36-month follow-up/before IVR 2.7±5.2 – 2.1±3.3 1.2±2.8
Final 3.2±6.4 2.0±2.6 4.7±4.2 1.6±4.2
Macular atrophy – central subfield 1 area
Initial 0.1±0.2 0.0±0.1 0.0±0.0 0.1±0.3
36-month follow-up/before IVR 0.3±0.4 – 0.2±0.3 0.1±0.3
Final 0.3±0.4 0.5±0.4 0.5±0.4 0.1±0.3











































































































   
   
   
   
   
   
   
   
   
   
   
   
   
   

























cally significant in the 3 treatment groups during the fol-
low-up (p < 0.05), but not in the dry maculopathy group. 
No statistically significant differences were found be-
tween the 3 treatment groups for the initial and final areas 
of macular atrophy (both total and central). However, a 
statistically significant difference was found between the 
dry maculopathy group and the 3 treatment groups for 
the final central area of macular atrophy (p < 0.05).
 The presence of macular atrophy (p = 0.023) and the 
presence of CNV (p = 0.017) at the initial visit correlated 
with the final total area of macular atrophy. 
 The hypoautofluorescent areas corresponding to 
chorioretinal atrophy measured in the final FAF images 
were separated in areas of peripapillary atrophy and ar-
eas of macular plus patchy atrophy ( table 4 ). A moder-
ate correlation was found between the hypoautofluores-
cent areas of macular and patchy atrophy measured in 
the FAFs and the areas of macular and patchy atrophy 
measured in the color fundus photographs, at the last 
visit (r = 0.574, p < 0.001). Also, a high correlation was 
found between the areas of peripapillary atrophy mea-
sured in the FAFs and the areas of peripapillary atrophy 
measured in the color fundus photographs (r = 0.815, 
p < 0.001).
 Evolution of BCVA 
 Progression of BCVA from the initial evaluation to 
the final visit was not statistically significant in the 4 
groups (p > 0.05). The initial BCVA was significantly dif-
ferent between the PDT group and PDT + IVR group 
(p = 0.036) and between the PDT group and dry macu-
lopathy group (p = 0.033). As for the final BCVA there 
were no statistically significant differences between the 4 
groups (p > 0.05;  table 1 ). Considering all eyes, a positive 
moderate correlation was found between final BCVA 
and initial and final SE, meaning that less myopic eyes 
had a better final visual acuity (r = 0.437, p = 0.012, and 
r = 0.458, p = 0.006, respectively). Final BCVA was also 
inversely correlated with total and central areas of macu-
lar atrophy, both at the initial and final visits (p < 0.01).
 Multivariate Regression Analysis 
 Regression analysis was performed to identify the pre-
dictive variables for the final area of macular atrophy and 
for the final BCVA. 
 For the final total area of macular atrophy analysis, the 
following variables were explored: initial and final age, 
time of follow-up, AL, SE, presence of staphyloma, type 
of myopic maculopathy, area of macular and patchy atro-
phy, and type and number of treatments used for myopic 
CNV (PDT, IVR and PDT + IVR). The following showed 
a predictive value for a larger final area of macular atro-
phy: greater initial age (p = 0.010) and final AL (p = 0.014), 
presence of staphyloma (p < 0.001) and a larger area of 
central atrophy in the initial evaluation (p = 0.011). Less 
myopic initial refraction was predictive of smaller areas 
(p = 0.006). The other variables had no predictive value 
for macular atrophy.
 For the final BCVA analysis we considered the follow-
ing variables: initial and final age, follow-up, AL, SE, pres-
ence of staphyloma, type of myopic maculopathy, area of 
macular and patchy atrophy (total and central), and type 
and number of treatments used for myopic CNV. We 
found that only the presence and a larger total area of 
macular atrophy in the final visit were predictive of worse 
final BCVA (p < 0.001, p = 0.008). 
 Discussion 
 We analyzed the long-term progression of myopic 
maculopathy and functional outcome in eyes treated for 
myopic CNV and in eyes without CNV. No significant 
differences in morphological and functional outcomes 
were found, on a long-term basis, for 3 different thera-
peutic approaches, PDT, IVR and PDT + IVR, and the 
morphological changes in treated eyes were more likely 
to be related with the natural progression of the myopic 
maculopathy than with the kind of treatment performed. 
 The analysis of myopic maculopathy progression was 
performed in a manner similar to Hayashi et al.  [10] , but 
Table 4.  Areas of hypoautofluorescence in the FAFs performed during the last visit
Final FAF PDT IVR PDT + IVR Dry maculopathy
Total area of hypoautofluorescence from peripapillary atrophy 8.5±8.5 5.5±4.0 7.0±6.3 3.7±3.5
Macular and patchy atrophy in total area 5.3±7.3 7.6±8.5 5.8±5.2 2.6±5.9













   
   
   
   
   
   
   
   
   
   
   
   
   
   

























we also evaluated the progression in eyes treated with 
PDT and/or IVR for myopic CNV. In the PDT group, 
with a mean follow-up of 8.5 years, the tessellated fundus 
prevalence was very low, and the prevalence of diffuse 
and patchy atrophy was higher and increased until the 
final visit. This is probably related to the advanced stage 
of progression of these eyes, which already developed 
CNV, and is in line with the progression patterns de-
scribed by Hayashi et al.  [10] . Some lacquer cracks also 
evolved into patchy atrophy, which explains the decrease 
in the first and again the increase in the latter, and con-
firms that lacquer cracks develop at an earlier stage than 
severer maculopathies  [10] ( fig. 4 ). Macular atrophy in-
creased during the follow-up affecting 80% of the PDT-
treated eyes at the final visit. This was somehow expected 
because macular atrophy is the most common complica-
tion of CNV. However, it was inferior to the rate of 90.1% 
described by Hayashi et al.  [10] in nontreated myopic 
CNV eyes with a mean follow-up of 11.8 years.
 The progression pattern found in the PDT + IVR 
group, which has a mean follow-up of 7.2 years, is similar 
to that of the PDT group. The prevalence of macular at-
rophy increased substantially until the final visit, even af-
ter switching to IVR, and affected all eyes in the final vis-
it ( fig. 4 ). This is important as the follow-up in the PDT + 
IVR group is inferior compared to the PDT group. This 
difference could be related to the persistence of active 
CNV in the PDT + IVR group, reflected by the need of 
more retreatments. Persistent disease could therefore 
lead to a superior chance of developing macular atrophy.
 In the IVR group, with a mean follow-up of 3.7 years, 
the progression pattern was different. Tessellated fundus, 
diffuse and patchy atrophy were found with a similar dis-
tribution, but they remained constant until the final visit. 
Macular atrophy however increased, affecting 70% of the 
eyes at the final visit. Despite the inferior follow-up, the 
prevalence of macular atrophy in the end was similar to 
that of the PDT group, and if we compare the rate after a 
similar period of time, we find that in the PDT group it 
was 53% after 3 years of follow-up. Calvo-Gonzalez et al. 
 [19]  also found that after 2 years of treatment with IVR for 
myopic CNV, 70.2% of the eyes developed atrophy around 
the regressed CNV, and more recently, Oishi et al.  [23] 
also reported development or enlargement of chorioreti-
nal atrophy in 72.7% of the eyes, 4 years after treatment 
with bevacizumab. Moreover, Hayashi et al.  [7] reported 
that after 3 years of natural progression of CNV 74.1% of 
untreated eyes developed macular atrophy, and after 5 
 Fig. 4.  a–c PDT group – 58-year-old woman, OS, initial BCVA of 
59 letters and final of 77 letters, –11.0 dpt.  a Lacquer crack with 
CNV before treatment.  b 36 months later macular atrophy devel-
oped around the regressed CNV, and patchy atrophy arose from 
the temporal side.  c Enlargement of patchy atrophy (77 months). 
 d–f PDT + IVR group – 39-year-old woman, OD, initial BCVA of 
40 letters and final of 27 letters; –17.0 dpt.  d Patchy atrophy and 
CNV before treatment.  e After PDT treatment, at 42 months, an 
active CNV was again detected, and the number and area of patchy 
lesions increased; treatment was switched to IVR at this point. 





























   
   
   
   
   
   
   
   
   
   
   
   
   
   

























years the prevalence was 96.3%. Therefore, the assertion 
of some authors that PDT leads to a superior development 
of macular atrophy compared to the natural evolution or 
treatment with anti-VEGF is questionable  [24–26] .
 In the dry maculopathy group the prevalence of tessel-
lated fundus was superior to treatment groups, and dif-
fuse and patchy atrophy were considerably lower. These 
eyes, which never developed CNV, are probably in an ear-
lier stage of myopic maculopathy. Although not statisti-
cally significant, they were less myopic compared to the 
treatment groups, and they were younger compared to 
the PDT and IVR groups. The relationship between these 
factors and the progression of myopic maculopathy was 
already shown by Hayashi et al.  [10] . In the final assess-
ment the rate of macular atrophy was much lower com-
pared to treated eyes, which is in accordance with the nat-
ural history of the disease for eyes that never developed 
CNV  [10] .
 In eyes treated for CNV the area of macular atrophy 
increased significantly until the final evaluation. This 
confirms previous reports that chorioretinal atrophy can 
develop long after CNV has regressed not only in non-
treated eyes, but also in eyes treated with PDT and/or an-
ti-VEGF  [7, 27, 28] . Therefore, more studies with long-
term follow-up are needed to determine the real effective-
ness of different treatments for myopic CNV. 
 Multivariate regression analysis showed that age, de-
gree of myopia, presence of staphyloma and a greater 
baseline central area of macular atrophy were predictive 
of greater areas of macular atrophy in the long term. Ac-
cording to some authors PDT could contribute to the de-
velopment of macular atrophy  [24, 26, 27] . However, 
these studies had a short follow-up, ranging from 12 to 24 
months only. In a more recent study, and after the obser-
vation of long-term results, Hayashi et al.  [7] state that in 
fact PDT apparently does not facilitate the development 
of macular atrophy compared to natural evolution, but 
treatment with intravitreal injection of bevacizumab 
could lead to a lower degree of macular atrophy, by pre-
venting its appearance. Baba et al.  [27] and Ruiz-Moreno 
and Montero  [20] suggested the same. However, the latter 
also explained that the appearance and degree of atrophy 
might just be the result of the natural history of the dis-
ease. Oishi et al. [23] also state that progression of atrophy 
is often an inevitable consequence in the long-term fol-
low-up of treated myopic CNV cases, but this is probably 
due to the natural history. Our results are more in line 
with this hypothesis, as the final area of macular atrophy 
was not significantly different between treatment groups 
in the long term. 
 Final BCVA was not significantly different between 
the 3 treatment groups either. This can be explained by 
the small sample size of the groups and the retrospective 
nature of the study, but the extended follow-up, some-
how, strengthens these results. They appear to be in con-
tradiction with previous reports of superior functional 
outcomes in eyes treated with anti-VEGF compared to 
eyes treated with PDT or combination treatment. How-
ever, those studies compared the functional outcome at 
the 1- and 2-year follow-up, and instead we evaluated it 
in eyes with a minimum follow-up of 3 years and a mean 
follow-up of 6.7 years  [25, 29–31] . The visual acuity sta-
bilization observed in the 3 treatment groups could be the 
result of the development and progression of macular at-
rophy around the regressed CNV. This would limit the 
initial benefits of the treatment in visual acuity so that 
with a longer follow-up, as is the case of this study, the 
potential superiority of one treatment over the other is 
lost. This hypothesis was already raised in some studies 
 [14, 20] . A recent study reported a significant visual acu-
ity gain 36 months after treatment of myopic CNV with 
ranibizumab  [32] , and another reported a significant gain 
at 48 months of follow-up, after treatment with both ra-
nibizumab and bevacizumab  [33] , but in these studies, 
some subjects had previously been treated with PDT. 
Plus, el Matri et al. [25] reported that 12 months after 
starting treatment with bevacizumab, the gain in BCVA 
was no longer significant. Calvo-Gonzalez et al.  [19] and 
Ruiz-Moreno and Montero  [20] , in a previous study, also 
found that after 2 years the gain in BCVA with anti-VEGF 
therapy was no longer significant. In their opinion, the 
decreased visual acuity during or after the second year 
was probably just part of the myopic degeneration. Oishi 
et al.  [23] also reported absence of a significant gain in 
BCVA by the 4-year follow-up examination after treat-
ment with bevacizumab, and he and his associates state 
that development and enlargement of chorioretinal atro-
phy frequently occurred and affected visual improvement 
in the long term. Thus, long-term prognosis of anti-VEGF 
therapy alone, especially for treatment-naïve myopic 
CNV, is still unclear  [23] .
 Considering the different phenotypes of myopic 
maculopathy, only macular atrophy correlated with the 
worst visual prognosis in univariate and multivariate re-
gression analysis. This was also found by Hayashi et al. 
 [10] in their natural history study of pathological myo-
pia. Final visual acuity also correlated with the initial 
and final areas of macular atrophy, and the final area 
was a negative predictor of visual outcome. Macular at-













   
   
   
   
   
   
   
   
   
   
   
   
   
   

























relation between time of follow-up and BCVA. Visual 
acuity is probably influenced by the morphological sta-
tus of the macula, changing over time, but not by time 
per se. Location of the atrophy also seems to be impor-
tant, since not only the total area of macular atrophy, 
but also the area of atrophy located in the central sub-
field correlated with final BCVA, in univariate analysis. 
Central location was perhaps not identified as a predic-
tor in multivariate analysis because almost all eyes had 
subfoveal or juxtafoveal CNV and therefore compro-
mise of the central macula. The predictive value of the 
total area of macular atrophy in BCVA represents a 
more pronounced degree of dysfunction of the macula 
with increasing atrophy. The presence and the area of 
macular atrophy are therefore a main predictor of vi-
sual prognosis in highly myopic eyes and may be re-
sponsible for the progressive reduction of treatment ef-
ficacy in the long term  [7, 23, 27] .
 There are important limitations to this study. Besides 
its retrospective design, the main limitation is the small 
number of eyes included. Although the overall group was 
not small, the subgroups were, the follow-up was differ-
ent, and there is no true control group. However, the ex-
tended follow-up strengthens and may explain the re-
sults, as for the first time, the long-term functional and 
morphological outcomes in highly myopic eyes without 
CNV and in eyes with myopic CNV treated with PDT 
and/or IVR were evaluated. 
 In conclusion, our study showed no statistically sig-
nificant differences in morphological and functional out-
comes on a long-term basis for 3 different therapeutic 
approaches: PDT, IVR and PDT + IVR. Morphological 
and functional changes in the long term are more likely 
to be related with the natural progression of treated myo-
pic CNV than with the kind of treatment performed.
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